Profile data is unavailable for this security.
About the company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
- Revenue in USD (TTM)146.07m
- Net income in USD-196.04m
- Incorporated2008
- Employees228.00
- LocationKaryopharm Therapeutics Inc85 Wells Avenue, Second FloorNEWTON 02459United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://karyopharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio Holdings Inc | 137.35m | -28.92m | 79.41m | 58.00 | -- | 0.7505 | 35.98 | 0.5781 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Polypid Ltd | 0.00 | -34.17m | 80.64m | 57.00 | -- | 7.35 | -- | -- | -2.26 | -2.26 | 0.00 | 0.6028 | 0.00 | -- | -- | -- | -143.79 | -105.84 | -252.10 | -143.44 | -- | -- | -- | -- | 1.82 | -27.54 | 0.0826 | -- | -- | -- | -17.73 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 30.83m | -26.01m | 90.98m | 71.00 | -- | -- | -- | 2.95 | -3.44 | -3.44 | 3.50 | -1.80 | 0.8352 | 1.09 | 8.75 | 434,211.30 | -70.48 | -71.91 | -217.79 | -111.91 | 91.36 | -- | -84.38 | -729.00 | 1.18 | -1.70 | 1.94 | -- | 47.66 | -- | -14.31 | -- | -47.58 | -- |
| Biostem Technologies Inc | 235.17m | 20.20m | 97.34m | 67.00 | 6.43 | 1.94 | 4.76 | 0.4139 | 0.9019 | 0.9019 | 11.60 | 2.98 | 2.82 | 2.61 | 4.65 | -- | 24.25 | -- | 55.07 | -- | 97.33 | -- | 8.59 | -- | 4.09 | -- | 0.0566 | -- | 1,708.93 | -- | 475.86 | -- | -- | -- |
| Alpha Cognition Inc | 7.43m | -19.47m | 106.10m | 52.00 | -- | 2.34 | -- | 14.29 | -1.37 | -1.37 | 0.5002 | 2.09 | 0.2894 | -- | 5.22 | 142,830.80 | -75.87 | -119.10 | -93.86 | -159.05 | 73.09 | -- | -262.18 | -- | 6.03 | -7.91 | 0.00 | -- | -- | -- | -6.34 | -- | -- | -- |
| Fortress Biotech Inc | 62.30m | -5.34m | 112.05m | 101.00 | -- | 2.00 | -- | 1.80 | -0.293 | -0.293 | 2.16 | 1.80 | 0.4039 | 1.50 | 4.35 | 616,861.40 | -34.90 | -54.95 | -51.59 | -102.13 | 71.56 | 62.39 | -86.41 | -227.71 | 1.97 | -10.63 | 0.4503 | -- | -31.76 | 9.50 | 18.61 | -- | 25.88 | -- |
| Whitehawk Therapeutics Inc | 14.38m | -15.62m | 134.32m | 22.00 | 20.98 | 0.8546 | -- | 9.34 | 0.1358 | 0.1358 | 0.2802 | 3.33 | 0.1138 | 0.5669 | 4.40 | 359,600.00 | -12.36 | -52.97 | -13.76 | -60.63 | 89.22 | -- | -108.58 | -372.67 | 16.76 | -- | 0.00 | -- | 6.69 | -- | 3.15 | -- | 47.49 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 152.00m | 1.00 | -- | 0.8486 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 146.07m | -196.04m | 157.39m | 228.00 | -- | -- | -- | 1.08 | -16.60 | -16.60 | 13.36 | -16.00 | 1.07 | 1.36 | 5.13 | 640,644.80 | -143.71 | -55.11 | -442.98 | -78.19 | 95.93 | 96.83 | -134.21 | -87.65 | 1.08 | -2.11 | 47.44 | -- | 0.5715 | 6.21 | -156.52 | -- | -- | -- |
| Sanara Medtech Inc | 101.90m | -6.24m | 168.97m | 141.00 | -- | 27.47 | -- | 1.66 | -0.7292 | -4.34 | 11.86 | 0.6885 | 1.28 | 2.47 | 8.78 | 722,724.30 | -8.03 | -15.12 | -10.00 | -18.64 | 92.25 | 88.92 | -6.29 | -14.70 | 1.60 | 0.3039 | 0.8801 | -- | 33.36 | 49.09 | -124.59 | -- | -33.05 | -- |
| BGM Group Ltd | 26.85m | -2.72m | 178.70m | 323.00 | -- | 0.5937 | -- | 6.66 | -0.2816 | -0.2816 | 1.38 | 1.85 | 0.2087 | 3.21 | 8.60 | 83,116.91 | -2.08 | -0.0792 | -2.36 | -0.1065 | 19.41 | 10.38 | -9.95 | -0.0921 | 1.45 | -0.3408 | 0.0087 | 2,560.18 | -45.99 | -11.45 | 81.46 | -- | 16.40 | -- |
| Tonix Pharmaceuticals Holding Corp | 10.30m | -99.22m | 193.70m | 81.00 | -- | 0.666 | -- | 18.81 | -20.11 | -20.11 | 1.69 | 22.73 | 0.0593 | 0.9665 | 2.75 | 127,148.10 | -57.12 | -61.84 | -63.76 | -68.67 | 34.31 | -- | -963.38 | -2,797.35 | 9.62 | -- | 0.00 | -- | 29.94 | -- | -11.47 | -- | 47.82 | -- |
| Journey Medical Corp | 59.40m | -8.66m | 210.69m | 41.00 | -- | 7.87 | -- | 3.55 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 221.66m | 111.00 | -- | 4.41 | -- | 10.59 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
Data as of Feb 17 2026. Currency figures normalised to Karyopharm Therapeutics Inc's reporting currency: US Dollar USD
38.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Affinity Asset Advisors LLCas of 22 Jan 2026 | 1.71m | 9.36% |
| Opaleye Management, Inc.as of 10 Oct 2025 | 1.57m | 8.57% |
| Millennium Management LLCas of 04 Feb 2026 | 1.01m | 5.51% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 700.99k | 3.83% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 451.10k | 2.46% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 440.00k | 2.40% |
| Adage Capital Management LPas of 31 Dec 2025 | 421.32k | 2.30% |
| Exome Asset Management LLCas of 31 Dec 2025 | 295.54k | 1.61% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 198.26k | 1.08% |
| Geode Capital Management LLCas of 31 Dec 2025 | 187.73k | 1.03% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
